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Aim: To determine the frequency and topographic distribution of cerebral microbleeds (CMBs) in de-
mentia with Lewy bodies (DLB) in comparison to CMBs in Alzheimer disease dementia (AD).
Methods: Consecutive probable DLB (n ¼ 23) patients who underwent 3-T T2* weighted gradient-
recalled-echo MRI, and age and gender matched probable Alzheimer's disease patients (n ¼ 46) were
compared for the frequency and location of CMBs.
Results: The frequency of one or more CMBs was similar among patients with DLB (30%) and AD (24%).
Highest densities of CMBs were found in the occipital lobes of patients with both DLB and AD. Patients
with AD had greater densities of CMBs in the parietal, temporal lobes and infratentorial regions
compared to DLB (p < 0.05).
Conclusion: CMBs are as common in patients with DLB as in patients with AD, with highest densities
observed in the occipital lobes, suggesting common pathophysiologic mechanisms underlying CMBs in
both diseases.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypointense foci on T2* Gradient Recalled Echo MRI associated
with cerebral microbleeds (CMBs) are found in approximately 24%e
33% of Alzheimer disease dementia (AD) patients [1e4]. Although
the number of CMB in patients with dementia with Lewy bodies
(DLB) appear to be similar to AD patients, the regional density of
CMBs referenced to lobar volumes have not been established inAD, Alzheimer disease; CAA,
eed; GRE, gradient-recalled-
et SW, Rochester, MN 55905,
rci).
Ltd. This is an open access article uDLB [5]. Lobar microbleeds, particularly in the occipital, posterior
temporal and patietal lobes are typically associated with amyloid
deposition and cerebral amyloid angiopathy (CAA) [6e8]. Because
a majority of patients with DLB have high amyloid-b (Ab) deposi-
tion on PET imaging [9e11], we hypothesized that patients
with DLB are at an increased risk for CMBs as much as patients with
AD. In this study, we investigated the density and topographic
distribution of CMB in patients with DLB compared to AD.
2. Methods
2.1. Subjects and clinical evaluations
Consecutive patients with probable DLB (n ¼ 23) with median
age of 69 (interquartile range [IQR] 64e74) years from the Mayonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Subject demographics (all subjects).
DLB (n ¼ 23) AD (n ¼ 46) P-value
No. microbleeds positive (%) 7 (30) 11 (24) 0.56
No. female (%) 3 (13) 13 (28) 0.16
Age at mri yrs. 69 (64, 74) 71 (62, 78) 0.72
Age at onset. 63 (57, 70) 64 (57, 70) 0.63
Disease duration, yrs. 6 (4, 10) 5 (4, 9) 0.63
Education, yrs. 16 (14, 18) 16 (14, 17) 0.90
APOE ε carrier, n (%) 9 (41) 33 (73) 0.01
CDR-Sum of boxes score 6 (4, 8) 4 (3, 7) 0.17
Dementia rating scale 124 (104, 130) 118 (103, 126) 0.88
Whole brain density, mean (sd) 1.39 (2.47) 5.51 (17.12) 0.12
Presence of vascular disease and risk factors for vascular disease
Cardiovascular disease (%) 4 (19) 8 (19) >0.99
Stroke/TIA (%) 0 (0) 1 (2) >0.99
Hypertension (%) 7 (32) 25 (54) 0.08
Diabetes (%) 2 (9) 1 (2) 0.55
Unless otherwise indicated, values shown are median (IQR). P values were calcu-
lated using Student's t test or chi-squared test as appropriate. Abbreviations: CDR,
Clinical Dementia Rating. Disease duration is years from onset date to scan date.
I. Gungor et al. / Parkinsonism and Related Disorders 21 (2015) 1101e11041102Clinic Alzheimer's Disease Research Center (ADRC), underwent a 3T
MRI examination from June 2010 until March 2012. Age and sex 2:1
matched patients with AD dementia (n ¼ 46) from the ADRC were
included as referent group. History of cardiovascular disease,
stroke, hypertension and diabetes were recorded through self
report at the time of MRI.
Patients with DLB fulﬁlled the Consortium criteria for probable
DLB [12] and patients with AD dementia fulﬁlled the NINCDS-
ADRDA criteria for probable AD [13]. Patients were excluded if
they had history of traumatic brain injury, hydrocephalus, intra-
cranial mass, or other neurologic diseases that may inﬂuence im-
aging ﬁndings.
This studywas approved by theMayo Clinic Institutional Review




A standardized MRI imaging protocol was performed on all
subjects included in the study using a 3.0 T scanner, including 1) a
3D magnetization prepared rapid acquisition gradient echo
(MPRAGE) sequence (TR/TE/T1 ¼ 2300/3/900 ms; ﬂip angle ¼ 8;
FOV¼ 26 cm; in-plane matrix¼ 256 256; phase FOV¼ 0.94; slice
thickness ¼ 1.2 mm; and 2) T2* a GRE sequence (TR/TE ¼ 200/
20ms; ﬂip angle¼ 12; FOV¼ 20 cm; in-plane matrix¼ 256 224;
phase FOV ¼ 1.00; slice thickness ¼ 3.3 mm).
2.2.2. Identiﬁcation of CMBs
All CMBs and superﬁcial siderosis were identiﬁed by a trained
neurologist and secondarily conﬁrmed by two radiologists experi-
enced in reading the T2* GRE images (K.K. and C.R.J.), who were
blinded to the diagnostic group. Deﬁnite CMBs were deﬁned as
small homogenous hypointense lesions up to 10 mm in diameter in
the gray or whitematter on T2* GRE images as previously described
[1]. Occasionally, it was not possible to make a deﬁnitive decision,
such as distinguishing a CMB from a vascular ﬂow-void. In such
instances, the CMB was labeled as “possible CMB” and was not
included in the analysis.
2.2.3. Tracking and registration of CMB to a common template
The location of each observed CMB was recorded in the coor-
dinate system of the image on which it was made. Findings
observed on these images were propagated into the coordinate
system of the image under evaluation. A T1 (MPRAGE) image of the
subject was registered and resampled into the space of the image
under evaluation. The T1 image carries an in-house modiﬁed
automated anatomic labeling atlas [14] deﬁning bilateral frontal,
parietal, temporal, and occipital lobar regions and deep/infra-
tentorial gray and white matter regions. Because the lobar regions
differ in volume, we calculated the regional CMB densities as
referenced to the volume of the region rather than simply count per
region, combining the right and left hemispheres.
2.3. Statistics
Clinical and demographic characteristics including the fre-
quency of CMB in DLB and AD patients were compared using a
Student's t-test or a chi-squared test as appropriate. Mean CMB
densities in patients with DLB and AD were compared using Stu-
dent's t-tests.
3. Results
Patients with DLB and AD dementia were matched on age andsex and they did not differ on education, duration of disease, and
clinical severity such as CDR-Sum of Boxes and Dementia Rating
Scale and history of cardiovascular risk factors or stroke. A signiﬁ-
cantly higher proportion of patients with AD dementia (73%) were
APOE ε4 carriers, compared to patients with DLB (41%) (Table 1).
There were 67 lesions labeled as deﬁnite CMB among the AD
and DLB subjects. A total of 18 subjects (7 DLB and 11 AD) had at
least one deﬁnite CMB identiﬁed on the T2* scan. The frequency of
total MBs was 24% in the AD group and 30% in the DLB group, with
no statistically signiﬁcant difference among the two groups
(Table 1).
One patient with DLB and seven patients with AD dementia had
multiple CMBs (2 CMBs in one DLB subject, and respectively 2, 2, 2,
5,10, 12, 22MBs in the AD patients. Remaining patients had a single
CMB. Three patients with AD (6.5%) had superﬁcial siderosis, in
contrast, superﬁcial siderosis was not identiﬁed in patients with
DLB.
All patients with superﬁcial siderosis were APOE ε4 carriers.
CMBs were as common in with APOE ε4 positive DLB patients (2/6;
33%) as APOE ε4 negative (5/17; 29%) (p ¼ 0.86; Chi-square test).
Differences in the regional distribution of CMBs were observed
among the DLB and AD groups. Considering the regional volumes,
within the AD group, CMBs were most densely concentrated in the
occipital lobes followed by parietal and temporal lobes, while lower
CMBs were observed in the frontal lobes and deep and infra-
tentorial grey and white matter regions. Within the DLB group,
CMBs were mostly concentrated in the occipital and frontal lobes,
followed by parietal and temporal lobes. No CMBs were found in
the deep or infratentorial regions. Patients with DLB showed a
signiﬁcantly lower mean CMB density in the deep or infratentorial
regions (p ¼ 0.046) and temporal lobes (p ¼ 0.04) compared to
patients with AD (Fig. 1).4. Discussion
This study showed that CMBs are common in patients with DLB.
Approximately one third of patients with DLB had one or more
CMBs. While the frequency of CMBs was similar in AD (24%) and
DLB (30%), differences were found in the lobar distributions.
We observed the highest concentration of CMBs in the occipital
lobes of patients with AD, which is consistent with the established
topographic distribution of CMBs in older adults [1e4]. CMBs that
concentrate more in the posterior brain regions, particularly the
occipital lobes, are thought to be associated with CAA [2,15,16].
Fig. 1. Mean microbleed density by region and diagnosis (left) and the difference of the Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) group means with 95%
conﬁdence intervals (right) P-values are extracted from Student's t-Test.
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cipital lobes in patients with DLB, it is not possible to link the oc-
cipital CMB in patients with DLB to CAA, because distribution of
CAA in DLB subjects (with or without AD co-pathology) has not
been established.
Interestingly, patients with DLB had a higher concentration of
CMBs not only in the occipital region, but also in the frontal lobe.
High CMB load in the frontal lobes is consistent with a previous
study [5], which reported a higher numbers of frontal CMB in pa-
tients with DLB compared to AD. However in contrast to our ﬁnd-
ings, occipital lobe CMB involvement was less than frontal lobe
involvement in DLB patients [5]. This discrepancy may be due to
our use of CMB densities in each lobe, normalizing the counts with
the lobar volumes. Reporting CMB counts rather than densities in
two regions that differ in volume may be misleading. Another
possible explanation to the discrepancies could be the variability
due to the small sample size in both studies.
In individuals with CAA, lobar CMBs tend to be located in the
posterior brain regions. A high occipital CMB density in AD patients
supports the hypothesis that CAA is one of the underlying pathol-
ogies associated with the occipital CMBs in AD [2]. However, the
distribution of CAA in patients with DLB with or without additional
AD pathology has not been established. Therefore it is not possible
to explain the higher occipital or frontal lobe CMB densities
observed in patients with DLB with CAA. However, DLB patients are
characterized by Ab deposition in the frontal lobes on PET imaging
[11], and CMB is associated with Ab deposition [1,3]. Therefore
CMBs in DLB may be associated with the increased vascular
permeability during Ab clearance, implicated for amyloid related
imaging abnormalities (ARIA) in AD immunotherapy trials [17].
In the current study none of the DLB patients had CMBs in the
deep or infratentorial regions. While this could be due to the lim-
itations of our sample size, CMBs located in the deep or infra-
tentorial regions were associated with cardiovascular risk factors,
presence of lacunar infarcts and white matter hyperintensities
suggesting hypertensive and atherosclerotic microangiopathy is
the underlying etiology [18]. Based on the absence of deep or
infratentorial CMBs in the current study, hypertensive and
atherosclerotic microangiopathy is less likely to be contributing toCMB pathophysiology in DLB than in AD. Interestingly DLB patients
in the current study were less likely to report hypertension in their
clinical history (32%) than AD (54%), however this difference did not
reach statistical signiﬁcance (p ¼ 0.08).
The main limitation of our study is the relatively small sample
size therefore the ﬁndings need to be conﬁrmed in a larger cohort.
Furthermore, the cases were not pathologically conﬁrmed to have
LB disease and AD pathology, and we matched the AD patients to
the DLB patients on age and gender. The AD patients in the current
study may not be fully representative, and the ﬁndings in AD
should be interpreted with caution. A high frequency of CMBs in
patients with DLB has important therapeutic implications. High
numbers of CMBs increase the risk of ARIA with vasogenic edema
and effusions (ARIA-E) in amyloid-modifying immunotherapies
[19,20]. Patients with DLB with high Ab load are candidates for such
therapies however; they may be at risk for ARIA-E as much as pa-
tients with AD. Furthermore, CMBs have to be considered before
starting anticoagulation therapy to elderly adults with dementia
because of the higher risk of further brain hemorrhage. Under-
standing the pathophysiology of cerebral CMB in patients with DLB
would help with decisions on such therapeutic approaches in DLB
patients.
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